EE301 Improvement in Work Productivity Loss and Associated Costs for Crohn's Disease Patients Receiving Ustekinumab in the United States: Findings from a Real-World Survey

Work-productivity loss (WPL) is an important contributor to the economic burden of Crohn ’s disease (CD). Ustekinumab (UST) is a biologic for treating adults with moderate-to-severe CD. We aimed to report WPL and associated costs in patients with CD receiving UST, relative to those with moderate-to-severe CD not receiving UST, in the real world.

Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: Z Ding, E Muser, J Izanec, A Roughley, R Lukanova, J Kershaw Source Type: research